hydroxychloroquine has been researched along with Graft-Versus-Host Disease in 14 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD)." | 9.12 | A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. ( Adkins, D; Devine, SM; Dipersio, JF; Fong, T; Goodnough, LT; Graubert, T; Khoury, HJ; Lopez, S; Shenoy, S; Tomasson, M; Trinkaus, K; Vij, R, 2007) |
| "We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice." | 8.79 | The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. ( Gilman, AL; Schultz, KR, 1997) |
| "To evaluate retinal toxicity in patients treated with high-dose hydroxychloroquine (HCQ) (Plaquenil, Sanofi Pharmaceuticals) for chronic graft-versus-host disease (GVHD)." | 7.81 | Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. ( Boyd, S; Easterbrook, M; Hammoudi, DS; Krema, H; Lipton, JH; Navajas, EV; Simpson, ER, 2015) |
| "Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with activity against graft-versus-host disease (GVHD)." | 7.72 | Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. ( Adkins, D; Brown, R; Dipersio, JF; Goodnough, LT; Horowitz, M; Khoury, H; Ma, MK; McLeod, HL; Shenoy, S; Trinkaus, K; Vij, R; Zhang, MJ, 2003) |
| "Hydroxychloroquine (HCQ) is a 4-aminoquinoline antimalarial drug used for the treatment of autoimmune diseases." | 6.69 | Hydroxychloroquine for the treatment of chronic graft-versus-host disease. ( Boyer, M; Cahill, R; Chan, KW; Cirenza, E; Frankel, S; Gehan, E; Gilman, AL; Goldman, FD; Mazumder, A; Mogul, A; Morris, C; Schultz, K, 2000) |
| "Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD)." | 5.12 | A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. ( Adkins, D; Devine, SM; Dipersio, JF; Fong, T; Goodnough, LT; Graubert, T; Khoury, HJ; Lopez, S; Shenoy, S; Tomasson, M; Trinkaus, K; Vij, R, 2007) |
| "We have recently shown that the lysosomotropic amine, chloroquine, can inhibit the development of graft-versus-host disease (GVHD) secondary to minor histocompatibility (MiHC) differences in mice." | 4.79 | The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. ( Gilman, AL; Schultz, KR, 1997) |
| "To evaluate retinal toxicity in patients treated with high-dose hydroxychloroquine (HCQ) (Plaquenil, Sanofi Pharmaceuticals) for chronic graft-versus-host disease (GVHD)." | 3.81 | Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. ( Boyd, S; Easterbrook, M; Hammoudi, DS; Krema, H; Lipton, JH; Navajas, EV; Simpson, ER, 2015) |
| "Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with activity against graft-versus-host disease (GVHD)." | 3.72 | Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. ( Adkins, D; Brown, R; Dipersio, JF; Goodnough, LT; Horowitz, M; Khoury, H; Ma, MK; McLeod, HL; Shenoy, S; Trinkaus, K; Vij, R; Zhang, MJ, 2003) |
| "Previously, it has been shown that the lysosomotropic amine, chloroquine, is effective in the prevention of graft-versus-host disease (GVHD) using murine models." | 3.69 | Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. ( Bader, S; Nelson, D; Schultz, KR, 1996) |
| "Using murine models, we have shown that the lysosomotropic amine, chloroquine, is effective in the prevention of graft-versus-host disease (GVHD) mediated by donor T cells reactive with recipient minor histocompatibility antigens (MiHCs)." | 3.69 | Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist? ( Bader, S; HayGlass, KT; Nelson, D; Schultz, KR; Wang, MD, 1997) |
| "Hydroxychloroquine (HCQ) is a 4-aminoquinoline antimalarial drug used for the treatment of autoimmune diseases." | 2.69 | Hydroxychloroquine for the treatment of chronic graft-versus-host disease. ( Boyer, M; Cahill, R; Chan, KW; Cirenza, E; Frankel, S; Gehan, E; Gilman, AL; Goldman, FD; Mazumder, A; Mogul, A; Morris, C; Schultz, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (35.71) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Navajas, EV | 1 |
| Krema, H | 1 |
| Hammoudi, DS | 1 |
| Lipton, JH | 1 |
| Simpson, ER | 1 |
| Boyd, S | 1 |
| Easterbrook, M | 1 |
| Cuvelier, GD | 1 |
| Kariminia, A | 2 |
| Fujii, H | 1 |
| Aslanian, S | 1 |
| Wall, D | 1 |
| Goldman, F | 1 |
| Grupp, SA | 3 |
| Dunn, SE | 1 |
| Krailo, M | 2 |
| Shapiro, LH | 1 |
| Gilman, A | 1 |
| Schultz, KR | 7 |
| Rozmus, J | 1 |
| Wynne, K | 1 |
| Satyanarayana, P | 1 |
| Gilman, AL | 6 |
| Goldman, FD | 3 |
| Sale, GE | 1 |
| Krailo, MD | 1 |
| Chen, Z | 1 |
| Langholz, B | 1 |
| Jacobsohn, DA | 1 |
| Chan, KW | 2 |
| Ryan, RE | 1 |
| Kellick, M | 1 |
| Neudorf, SM | 1 |
| Godder, K | 1 |
| Sandler, ES | 1 |
| Sahdev, I | 1 |
| Sanders, JE | 1 |
| Wall, DA | 1 |
| Khoury, H | 1 |
| Trinkaus, K | 2 |
| Zhang, MJ | 1 |
| Adkins, D | 2 |
| Brown, R | 1 |
| Vij, R | 2 |
| Goodnough, LT | 2 |
| Ma, MK | 1 |
| McLeod, HL | 1 |
| Shenoy, S | 2 |
| Horowitz, M | 1 |
| Dipersio, JF | 2 |
| Bolaños-Meade, J | 1 |
| Zhou, L | 1 |
| Hoke, A | 1 |
| Corse, A | 1 |
| Vogelsang, G | 1 |
| Wagner, KR | 1 |
| Fong, T | 1 |
| Devine, SM | 1 |
| Tomasson, M | 1 |
| Lopez, S | 1 |
| Graubert, T | 1 |
| Khoury, HJ | 1 |
| Beams, F | 1 |
| Tefft, M | 1 |
| Mazumder, A | 2 |
| Nelson, D | 2 |
| Bader, S | 2 |
| Wang, MD | 1 |
| HayGlass, KT | 1 |
| Kossard, S | 1 |
| Ma, DD | 1 |
| Mogul, A | 1 |
| Morris, C | 1 |
| Boyer, M | 1 |
| Cirenza, E | 1 |
| Gehan, E | 1 |
| Cahill, R | 1 |
| Frankel, S | 1 |
| Schultz, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease[NCT00031824] | Phase 3 | 82 participants (Actual) | Interventional | 2002-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Graft-Versus-Host Disease
| Article | Year |
|---|---|
The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease.
Topics: Animals; Antigen Presentation; Bone Marrow Transplantation; Chloroquine; Clinical Trials as Topic; C | 1997 |
5 trials available for hydroxychloroquine and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.
Topics: Adolescent; Antibodies; Biomarkers; Bone Marrow Transplantation; CD13 Antigens; Child; Child, Presch | 2010 |
Early and late extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 cytokine profiles: findings of the Children's Oncology Group Study ASCT0031.
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Cytokines; Double-Blind Method; Female; | 2011 |
Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children's Oncology Group study.
Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Female; Graft vs H | 2012 |
A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Chronic Disease; Disease-Free Survival; Double-Blind Method; Female; Graft vs Host Disease; H | 2007 |
Hydroxychloroquine for the treatment of chronic graft-versus-host disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Ch | 2000 |
8 other studies available for hydroxychloroquine and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.
Topics: Adult; Aged; Antimalarials; Chronic Disease; Color Vision Defects; Electroretinography; Female; Graf | 2015 |
Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation.
Topics: Adolescent; Adult; Antigens, CD; Bone Marrow Transplantation; Cause of Death; Enzyme Inhibitors; Gra | 2003 |
Hydroxychloroquine causes severe vacuolar myopathy in a patient with chronic graft-versus-host disease.
Topics: Biopsy; Bone Marrow Transplantation; Chronic Disease; Enzyme Inhibitors; Graft vs Host Disease; Huma | 2005 |
The effect of hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease.
Topics: Cyclosporine; Cytotoxicity, Immunologic; Graft vs Host Disease; Humans; Hydroxychloroquine; Lymphocy | 1996 |
Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid.
Topics: Adult; Antigens, Differentiation, B-Lymphocyte; Chloroquine; Cyclosporine; Drug Synergism; Graft vs | 1996 |
Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?
Topics: Animals; Cell Survival; Cells, Cultured; Chloroquine; Concanavalin A; Cyclosporine; Drug Synergism; | 1997 |
Acral keratotic graft versus host disease simulating warts.
Topics: Bone Marrow Transplantation; Chronic Disease; Diagnosis, Differential; Graft vs Host Disease; Humans | 1999 |
Treatment of chronic GVHD.
Topics: Chronic Disease; Graft vs Host Disease; Humans; Hydroxychloroquine; Randomized Controlled Trials as | 2000 |